Literature DB >> 26073060

Selecting the proper pediatric dose: It is more than size that matters.

G L Kearns1.   

Abstract

Appropriate pediatric dose selection remains one of the most vexing clinical problems faced by healthcare professionals who are charged to provide medical care to infants and children. While body size does reflect the ontogeny of processes that govern drug disposition, there are extremes of disease that perturb the expected relationships.
© 2015 ASCPT.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26073060      PMCID： PMC4543563          DOI： 10.1002/cpt.168

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.903


  10 in total

1.  Altered energy metabolism in anorexia nervosa.

Authors:  J Russell; L A Baur; P J Beumont; S Byrnes; G Gross; S Touyz; S Abraham; S Zipfel
Journal:  Psychoneuroendocrinology       Date:  2001-01       Impact factor: 4.905

2.  The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype.

Authors:  A Gaedigk; S D Simon; R E Pearce; L D Bradford; M J Kennedy; J S Leeder
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

3.  Body size and metabolic rate.

Authors:  M KLEIBER
Journal:  Physiol Rev       Date:  1947-10       Impact factor: 37.312

Review 4.  Dosing in children.

Authors:  N Holford
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

Review 5.  Tips and traps analyzing pediatric PK data.

Authors:  Brian J Anderson; Nick H G Holford
Journal:  Paediatr Anaesth       Date:  2011-03       Impact factor: 2.556

Review 6.  The challenge of obesity in paediatric leukaemia treatment: it is not just size that matters.

Authors:  Jaszianne Tolbert; Gregory L Kearns
Journal:  Arch Dis Child       Date:  2014-10-21       Impact factor: 3.791

7.  Estimation of glomerular filtration rate in anorectic adolescents.

Authors:  L P Brion; M A Boeck; B Gauthier; M P Nussbaum; G J Schwartz
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

Review 8.  Developmental pharmacology--drug disposition, action, and therapy in infants and children.

Authors:  Gregory L Kearns; Susan M Abdel-Rahman; Sarah W Alander; Douglas L Blowey; J Steven Leeder; Ralph E Kauffman
Journal:  N Engl J Med       Date:  2003-09-18       Impact factor: 91.245

9.  Distribution volume, metabolic clearance and plasma half disappearance time of exogenous luteinizing hormone releasing hormone in normal women and women with obesity and anorexia nervosa.

Authors:  K Chikamori; F Suehiro; T Ogawa; K Sato; H Mori; I Oshima; S Saito
Journal:  Acta Endocrinol (Copenh)       Date:  1981-01

Review 10.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.

Authors:  K R Crews; A Gaedigk; H M Dunnenberger; J S Leeder; T E Klein; K E Caudle; C E Haidar; D D Shen; J T Callaghan; S Sadhasivam; C A Prows; E D Kharasch; T C Skaar
Journal:  Clin Pharmacol Ther       Date:  2014-01-23       Impact factor: 6.875
  10 in total
  3 in total

Review 1.  Design and conduct of early phase drug studies in children: challenges and opportunities.

Authors:  Michael Rieder; Daniel Hawcutt
Journal:  Br J Clin Pharmacol       Date:  2016-08-08       Impact factor: 4.335

2.  Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants.

Authors:  Christoph P Hornik; Nikolas J Onufrak; P Brian Smith; Michael Cohen-Wolkowiez; Matthew M Laughon; Reese H Clark; Daniel Gonzalez
Journal:  Cardiol Young       Date:  2017-08-08       Impact factor: 1.023

3.  Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates.

Authors:  Christoph P Hornik; Daniel K Benjamin; P Brian Smith; Michael J Pencina; Adriana H Tremoulet; Edmund V Capparelli; Jessica E Ericson; Reese H Clark; Michael Cohen-Wolkowiez
Journal:  J Pediatr       Date:  2016-08-10       Impact factor: 6.314
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.